English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Benign prostatic hyperplasia(BPH) is a very common condition among elderly men causing significant symptoms with urination and results in bladder outlet obstruction. Silodosin is a recently developed selective α1A-adrenoreceptor antagonist for the medical treatment of BPH. This study is to evaluate the efficacy and safety of silodosin 8mg in geriatric patients with BPH. Materials And Methods: A prospective observational study was done at K.S.Hegde Medical Academy, Mangalore, India on 53 patients with BPH during August 2014 to march 2016. These patients were aged ≥ 50 years, with international prostate symptom score(IPSS) of ≥12 and having a peak urinary flow rate (PFR) <15 ml/sec on uroflowmetry. Patients were treated with silodosin 8mg once daily and were followed up. We assessed the changes in IPSS,PFR and adverse effects of the drug at baseline, 1 month and 3 months after treatment. Results: The mean age of subjects was 63.32±6.6. Their mean IPSS scores were 25.06±2.87,18.91±3.92, 16.19±4.9at baseline, 1month and 3 months respectively with significant improvement(p<0.0001). There was also a significant increase in the peak urinary flow rate(PFR) (p<0.0001). The only adverse effect encountered was retrograde ejaculation. In three out of 5 patients this problem subsided without any intervention. Conclusions: Silodosin is an effective and well tolerated drug producing significant improvement in IPSS and PFR with fewer cardiovascular side effects in this frail population. Therefore silodosin can be used as a first line agent in BPH and continuation of this drug will avoid a surgical intervention.

A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia